BI Asset Management Fondsmaeglerselskab A S grew its holdings in The Clorox Company (NYSE:CLX - Free Report) by 42.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,232 shares of the company's stock after purchasing an additional 22,567 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned about 0.06% of Clorox worth $7,900,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp lifted its stake in Clorox by 3.5% in the third quarter. State Street Corp now owns 8,434,277 shares of the company's stock valued at $1,039,946,000 after buying an additional 282,794 shares during the period. Invesco Ltd. increased its stake in shares of Clorox by 22.1% in the 4th quarter. Invesco Ltd. now owns 4,880,341 shares of the company's stock valued at $492,085,000 after acquiring an additional 884,751 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Clorox by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 3,172,233 shares of the company's stock valued at $318,613,000 after acquiring an additional 10,060 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Clorox by 15.7% during the 4th quarter. Van ECK Associates Corp now owns 3,136,405 shares of the company's stock valued at $316,244,000 after acquiring an additional 426,433 shares during the period. Finally, Two Sigma Investments LP boosted its stake in Clorox by 33.8% during the third quarter. Two Sigma Investments LP now owns 1,740,175 shares of the company's stock worth $214,564,000 after acquiring an additional 439,797 shares in the last quarter. Institutional investors own 78.53% of the company's stock.
Insider Activity at Clorox
In related news, Director Pierre R. Breber purchased 5,000 shares of Clorox stock in a transaction dated Tuesday, May 5th. The stock was bought at an average cost of $85.82 per share, for a total transaction of $429,100.00. Following the completion of the transaction, the director owned 18,000 shares in the company, valued at $1,544,760. This trade represents a 38.46% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.63% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on CLX shares. TD Cowen increased their price target on Clorox from $98.00 to $111.00 and gave the stock a "hold" rating in a report on Tuesday, March 31st. Weiss Ratings raised shares of Clorox from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, April 13th. Citigroup lowered their target price on shares of Clorox from $110.00 to $97.00 and set a "neutral" rating on the stock in a report on Friday, May 1st. Jefferies Financial Group dropped their price target on shares of Clorox from $139.00 to $125.00 and set a "buy" rating on the stock in a research report on Monday, May 4th. Finally, UBS Group cut their price target on Clorox from $110.00 to $96.00 and set a "neutral" rating for the company in a research note on Friday, May 1st. One research analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and five have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Reduce" and an average price target of $103.40.
Get Our Latest Research Report on Clorox
Clorox Stock Up 0.1%
CLX stock opened at $95.90 on Monday. The stock has a market cap of $11.60 billion, a P/E ratio of 15.57, a P/E/G ratio of 0.50 and a beta of 0.56. The stock's fifty day simple moving average is $95.71 and its two-hundred day simple moving average is $104.81. The company has a current ratio of 0.84, a quick ratio of 0.65 and a debt-to-equity ratio of 27.03. The Clorox Company has a 1-year low of $84.70 and a 1-year high of $132.03.
Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $1.64 earnings per share for the quarter, topping the consensus estimate of $1.55 by $0.09. The company had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.67 billion. Clorox had a return on equity of 443.64% and a net margin of 11.18%.The firm's quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.45 EPS. Clorox has set its FY 2026 guidance at 5.450-5.650 EPS. Analysts expect that The Clorox Company will post 5.61 EPS for the current year.
Clorox Company Profile
(
Free Report)
The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company's flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.
Clorox's diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.
See Also
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Clorox, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.
While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.